**Core tip:** Yīn-Chén-Hāo decoction (YCHD) was a classical prescription for more than 1800 years in China. This review summarizes the efficacy of YCHD in liver disease from clinical trials and its mechanisms of action *in vitro* and *in vivo*. Studies indicate that YCHD can modulate various molecular pathways in liver disease. YCHD is widely used in clinical settings for the treatment of liver diseases, and could be a safe and novel therapeutic drug for liver injury worldwide.

INTRODUCTION
============

Yīn-Chén-Hāo decoction (YCHD) was first described in the "*Treatise on Febrile Diseases*" by Zhong-Jing Zhang during the Eastern Han Dynasty (AD 25-220). It a classic prescription in traditional Chinese medicine (TCM) that is mainly used for internal stasis heat and jaundice arising from Yang Ming disease and malnutrition, with doctors also widely using this prescription for heat jaundice. Modern usage of YCHD includes treatment for acute icteric infectious hepatitis along with other herbal medicines. YCHD is also used for hepatic diseases and has some uses in internal medicine, surgery, and pediatrics (Table [1](#T1){ref-type="table"}). This paper discusses studies on YCHD and its mechanisms in the treatment of hepatic diseases.

###### 

Clinical trials using Yīn-Chén-Hāo decoction

  **Herb or compound**                                              **Dose and course of treatment**                                    **Combined medication**                                                                                  **Case/control**   **Disease type**                                                                               **Symptoms**                                                                                    **Efficacy**                                                                                                                                                                                           **Positive control drug**                                                                                                                                                             **Side effects**   **Ref**.
  ----------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ------------------ ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ----------
  YCHD                                                              From 28^th^ wk of pregnancy, decocted with water, daily, 4 wk       From 36^th^ wk of pregnancy, both groups, + administration of 30 mg phenobarbital, twice a day, orally   81/76              Maternal-fetal ABO blood group incompatibility                                                 IgG anti-A/B antibody titer, growth in fetus, neonatal jaundice                                 Reduced antibody titer, reduced jaundice incidence rate, reduced TBIL                                                                                                                                  Vitamin C 0.5 g + 100 IU coenzyme A + 40 mg adenosine triphosphate, IVGTT                                                                                                             None               \[61\]
  YCHD                                                              Modified YCHD, decocted with water daily; orally, twice a day       1000 mg transmetil injection, IVGTT                                                                      38/30              Hyperbilirubinemia induced by viral hepatitis                                                  Clinical symptoms, liver function, bilirubin                                                    Symptoms, bilirubin levels significantly improved due to liver function                                                                                                                                Vitamin C, vitamin B6, diammonium                                                                                                                                                     None               \[62\]
  Modified YCHD                                                     Decocted with water, daily, 10 d                                    Routine Western medical treatment                                                                        34/34              Pathological neonatal jaundice                                                                 Time of jaundice disappearance, jaundice degree, TBIL                                           Time jaundice disappearance is shut down, liver TBIL significantly decreased                                                                                                                           Routine Western medicine therapy, etiological treatment, light therapy, phenobarbital, albumin for patients with high bilirubin, gamma globulin for patients with hemolytic disease   None               \[63\]
  Modified YCHD                                                     Decocted with water, daily, 14 d                                    Plasma exchange                                                                                          20/20              Hepatitis B combined with hyperbilirubinemia                                                   Liver function, prothrombin activity                                                            TBIL significantly decreased effective rate of treatment group compared with significantly increased control group                                                                                     Plasma exchange                                                                                                                                                                       None               \[64\]
  Modified YCHD                                                     Decocted with water, daily, orally, 28 d                            Mask with the function of removing heat and eliminating stasis                                           31/29              Gastrointestinal damp-heat acne                                                                Acne coalescence condition                                                                      Increased total effective rate of acne coalescence, average efficacy index statistically significantly decreased                                                                                       Danshentong capsules for oral use, vitamin E emulsifiable paste for external use                                                                                                      None               \[65\]
  Modified YCHD                                                     Decocted with water, daily, orally, 7 d                             None                                                                                                     32/34              Juvenile bronchial asthma                                                                      Asthma symptoms                                                                                 Curative effect of treatment group significantly better than control group; fade time of cough, sputum, and wheezing in treatment group significantly shorter than control group (*P* \< 0.05)         Normal saline, dexamethasone injection, ambroxol hydrochloride injection, aerosol inhalation, twice a day, 3-7 days, additional antibiotics for infected individual                   None               \[66\]
  Modified YCHD                                                     Decocted with water, daily, orally                                  EST + endoscopic stone extraction + ENBD                                                                 24/24              Choledocholithiasis                                                                            TBIL, DBIL, AKP, GGT, ALT, daily bile reflux                                                    Observed indicators improved significantly, daily bile reflux significantly higher than control group (*P* \< 0.05)                                                                                    Anti-infection, hepatoprotective, prevents fluid and electrolyte imbalance, symptomatic supportive care                                                                               None               \[67\]
  Yin-Zhi-Huang injection                                           10 mL + 20 mL glucose solution, IVGTT, daily, 15 wk                 Kadai surgery, antibiotic treatment, hormone treatment, +vitamin K1, +ursodeoxycholic acid               18/14              Biliary atresia                                                                                TBIL, DBIL, ALT, AST                                                                            Observation target significantly improved (*P* \< 0.05)                                                                                                                                                None                                                                                                                                                                                  None               \[68\]
  Yin-Zhi-Huang granule                                             1.0 g, 3 times a day, orally, 7 d                                   Blue light irradiation, 8 h daily + 105 mg bifid-triple viable capsule, twice a day orally, 7 d          150/133/141        Neonatal jaundice                                                                              Time of jaundice disappearance, transcutaneous bilirubin                                        Time of jaundice disappearance significantly reduced, transcutaneous bilirubin level significantly reduced (*P* \< 0.05)                                                                               Blue light irradiation                                                                                                                                                                None               \[69\]
  Yin-Zhi-Huang granule                                             3.3 mL, 3 times a day, orally, 5 d                                  None                                                                                                     120/120/120        Pathological neonatal jaundice                                                                 Bilirubin concentration, time of jaundice disappearance                                         Plasma bilirubin level significantly reduced, total effective rate significantly increased                                                                                                             Tuihuang mixture                                                                                                                                                                      None               \[70\]
  Yin-Zhi-Huang injection                                           5 mL + 10% glucose solution 50 mL, IVGTT, daily, 10 d               ATP, coenzyme A, inosine, vitamin C, glucuronolactone                                                    46/12              Infantile hepatitis syndrome                                                                   Treatment results (cured, improved, invalid), serum TBIL, ALT value, size of liver and spleen   Cure rate, total effective rate significantly increased, plasma bilirubin level significantly reduced, obvious change to liver and spleen size                                                         ATP, coenzyme A, inosine, vitamin C, glucuronolactone                                                                                                                                 None               \[71\]
  Modified compound Yīn-Chén recipe                                 Twice a day                                                         None                                                                                                     215/120            Maternal-fetal ABO blood group incompatibility-induced neonatal jaundice                       Antibody titer, neonatal jaundice incidence, jaundice degree                                    Antibody titer and neonatal jaundice incidence much lower post-treatment, TCM treatment before delivery failed to reduce jaundice degree                                                               None                                                                                                                                                                                  None               \[72\]
  ICKT                                                              7.5 g, daily, orally                                                None                                                                                                     1                  Acute cholestatic hepatitis                                                                    Clinical course of patient                                                                      TBIL level began to decrease, liver biopsy showed chronic active hepatitis with mild fibrosis                                                                                                          Predonine                                                                                                                                                                             None               \[73\]
  ICKT                                                              7.5 g, daily, orally                                                None                                                                                                     50/50              Persistent hyperbilirubinemia as a symptom of post-operative liver failure after hepatectomy   Choleretic effect                                                                               ICKT group showed significant decrease compared with control group in indirect bilirubin levels                                                                                                        None                                                                                                                                                                                  None               \[74\]
  Modified compound Yīn-Chén recipe                                 Modified compound Yīn-Chén recipe decoction, orally                 Routine Western medical treatment                                                                        30/30              Chronic severe hepatitis                                                                       Liver function indices, complication incidences, score of TCM syndromes, clinical effects       Treatment group better than control group (*P* \< 0.05)                                                                                                                                                Basic Western medical treatment                                                                                                                                                       None               \[75\]
  Modified YCHD                                                     Retention enema, daily                                              Routine comprehensive treatment                                                                          30/30              Chronic severe hepatitis                                                                       Liver function indices, endotoxin, blood ammonia                                                Treatment group better than control group (*P* \< 0.05) in improvement of clinical symptoms, endotoxin, blood ammonia, ALT, AST, and TBIL                                                              Lactulose medicated by retention enema                                                                                                                                                None               \[76\]
  Modified Artemisiae                                               Twice a day                                                         Ursodeoxycholic acid                                                                                     30/30              Primary biliary cirrhosis                                                                      Clinical effect, biochemistry indicators, immunoglobulin levels                                 Treatment group better than control group (*P* \< 0.05) in clinical effect and biochemistry indicators, insignificantly decreased immunoglobulin levels (*P* \> 0. 05)                                 Ursodeoxycholic acid                                                                                                                                                                  None               \[77\]
  Scopariae decoction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Modified YCHD                                                     Twice a day                                                         Conventional treatment, phenobarbital (blue light-struck)                                                30/29              Neonatal hyperbilirubinemia                                                                    Clinical effect                                                                                 Treatment group better than control group (*P* \< 0.05) in clinical effect                                                                                                                             Conventional treatment (phenobarbital, blue light-struck)                                                                                                                             None               \[78\]
  Lidan Xiaohuang decoction                                         50-100 mL 2-3 times a day, orally                                   Routine                                                                                                  35/31              Obstructive jaundice, post-operative persistent jaundice                                       Bilirubin                                                                                       Treatment group better than control group (*P* \< 0.01)                                                                                                                                                Acupuncture therapy                                                                                                                                                                   None               \[79\]
  Western medical treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Qing-Re-Li-Shi formula                                            Twice a day, 90 d                                                   None                                                                                                     60                 Chronic hepatitis B                                                                            Liver function comparison, hepatitis B virus marker comparison                                  Contents of ALT, AST, AKP, G, TBIL, DBIL improved (*P* \< 0.01); negative conversion rates of 16.7% HbsAg, 21.2% HbeAg, and 35.0% HBV                                                                  None                                                                                                                                                                                  None               \[80\]
  Modified compound Yīn-Chén recipe                                 Twice a day                                                         Triple anti-Hp therapy                                                                                   30/30              Hp-positive rosacea                                                                            Clinical effective rate, Hp- positive rate, serum IL-8, TNF-α                                   Clinical effective rate in treatment group better than control group (*P* \< 0.05); Hp- positive rate, serum IL-8, and TNF-α in treatment group significantly lower than control group (*P* \< 0.01)   Triple anti-Hp therapy                                                                                                                                                                None               \[81\]
  Modified compound Yīn-Chén recipe                                 Twice a day                                                         Routine                                                                                                  120/90             Viral hepatitis jaundice                                                                       Jaundice disappearance, liver function improvement                                              Clinical effective rate and liver function in treatment group better than control group (*P* \< 0.05)                                                                                                  Routine                                                                                                                                                                               None               \[82\]
  Western medical treatment                                         Western medical treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Obstructive jaundice                                              Twice a day                                                         Obstructive jaundice                                                                                     28/26              Obstructive jaundice                                                                           TBIL, DBIL                                                                                      More obvious decline of TBIL and DBIL in experimental group (*P* \< 0.05)                                                                                                                              Obstructive jaundice                                                                                                                                                                  None               \[83\]
  Supplement YCHD                                                   Twice a day                                                         Routine                                                                                                  30/30              Severe chronic hepatitis B                                                                     Liver function, gross effective rate, mortality rate                                            YCHD significantly improved liver function and gross effective rate, mortality rate lower than control group (*P* \< 0.05)                                                                             Routine                                                                                                                                                                               None               \[84\]
  Western medical treatment for protective liver, plasma exchange   Western medicinal treatment for protective liver, plasma exchange                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  YCHD                                                              Twice a day                                                         Routine                                                                                                  30/30              Intrahepatic cholestasis of pregnancy                                                          Pruritus score, serum bile acid level, Apgar score, body weight                                 Pruritus score and serum bile acid level lower than control group (*P* \< 0.05, *P* \< 0.01, respectively); Apgar score and body weight better than control group (*P* \< 0.01)                        Routine                                                                                                                                                                               None               \[85\]
  Western medical treatment for protective liver                    Western medical treatment for protective liver                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

YCHD: Yīn-Chén-Hāo decoction; TBIL: Total bilirubin; IVGTT: Intravenous glucose tolerance test; EST: Endoscopic sphincterotomy; ENBD: Endoscopic nasobiliary drainage; DBIL: Direct bilirubin; AKP: Alkaline phosphatase; GTT: Gamma-glutamyl transferase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ATP: Adenosine triphosphate; TCM: Traditional Chinese medicine; ICKT: In-Chin-Ko-To; HBV: Hepatitis B virus; Hp: Haptoglobin.

Classic Chinese formulae include four elements: the monarch drug, the minister drug, the assistant drug, and the servant drug; the monarch drug plays the most important role in the formula, the assistant drug increases the effectiveness of the monarch drug, the minister drug helps the monarch and minister drugs reach their target positions, and the servant drug can reduce the adverse effects or increase the potency of the entire formula\[[@B1]\].

YCHD (Figure [1](#F1){ref-type="fig"}) is comprised of 12 g capillaris (*Artemisia capillaris*), 9 g gardenia (*Gardenia jasminoides*), and 9 g rhubarb (*Rheum rhabarbarum*). Capillaris is the monarch drug, and can clear heat and dampness and remove jaundice. Gardenia is the minister drug, and can clear heat-fire and damp-heat in the triple burner, and remove pathogenic factors from the urine. Rhubarb is both the assistant and servant drug, and acts to purge heat from the bowels, cool the blood, detoxify, dispel stasis, and dredge the meridians. The three drugs together prevent stasis, promote bowel movement, and guide stagnant heat to be excreted alongside the stool. YCHD is usually used twice daily. In an animal study with rats, total bilirubin (TBIL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were improved and the blood level of scoparone was higher for longer when YCHD was administered once *vs* twice or three times daily. The exact mechanism of this effect has yet to be determined\[[@B2]\].

![Composition of Yīn-Chén-Hāo decoction.](WJG-23-1125-g001){#F1}

CHEMICAL COMPOSITION OF YCHD
============================

YCHD has broad prospects for application in the field of liver disease, particularly in the treatment of hepatitis with jaundice; for example, it promotes bilirubin metabolism, can prevent liver damage, and inhibits hepatic apoptosis, hepatic stellate cell (HSC) activation, and collagen synthesis\[[@B3]\]. Studies on its chemical composition have determined some effective compounds found in YCHD. Capillaris mainly contains five classes\[[@B4]\] of active compounds: coumarins (*e.g*., scoparone); flavonoids (*e.g*., arcapillin, 5,3',4',hydroxy-6,7-dimethoxycoumarin, cirsimaritin, 3'-methoxy thistle flavin); chromones (*e.g*., capillarisn, 7-a methyl wormwood color ketone, 4'-a methyl wormwood color ketone, 1-methoxy 4' methyl 6 gall color ketone); organic acids (*e.g*., chlorogenic acid, coumaric acid A and B); and alkaloids (*e.g*., alkynes, monoterpenes, sesquiterpenes, water-soluble polypeptides). Rhubarb mainly contains five classes of active compounds: anthraquinones (including two types of free anthraquinones like rhein, emodin, aloe emodin, chrysophanol, and physcion; and bound anthraquinones like anthraquinone glycoside and dianthrone glucosides); tannins (*e.g*., gallic acid, D-catechin); stilbenes (*e.g*., rhaponticin, piceatannol, resveratrol, 3',4',5-hydroxyl stilbene, rhaponticin-2"-O-gallate, rhaponticin-6"-O-gallate); volatile oils (*e.g*., palmitic acid, hexacosanoic acid, palmitic ethyl ester, dibutyl phthalate); and rhubarb polysaccharides. Gardenia mainly contains five classes of active compounds: gardenosides (*e.g*., geniposide, hydroxyl gardenoside, caryptoside, gardoside, scandoside methyl ester, geniposidic acid); pigments (*e.g*., crocin, crocetin); organic acids (*e.g*., chlorogenic acid, bitter saffron acid, alicyclic acid, 3-oxygen α coffee α mustard acyl α 4-oxygen quinic acid); volatile oils (*e.g*., linoleic acid, palmitic acid); and gardenia polysaccharides.

One study identified 45 compounds from YCHD, with 21 found in rat blood after oral administration. After studying the influence of different herbs alone compared with the whole YCHD decoction, investigators found eight compounds that are selectively absorbed into the bloodstream only after administration of all herbs from the YCHD decoction. Each compound had a significant effect on protecting the liver and gallbladder\[[@B5]\] (Figure [2](#F2){ref-type="fig"}).

![Molecular structures of compounds found in Yīn-Chén-Hāo decoction.](WJG-23-1125-g002){#F2}

The biological effects of many ingredients in YCHD reflect the therapy of the entire formula (Table [2](#T2){ref-type="table"}). For example, rhein may relieve cellular insult through its anti-inflammatory activity in combination with nitric oxide (NO) from L-arginine\[[@B6]\]. Rhein can improve liver function and remove hepatic fibrosis *via* anti-inflammatory and antioxidant pathways, and inhibit TGF-α activity and HSC activation\[[@B7]\]. Chlorogenic acid, another critical active ingredient of YCHD, can counteract liver injury at various levels by preventing apoptosis and oxidative stress damage. More specifically, both the glutathione and thioredoxin antioxidant systems and the mitogen-activated protein kinase (MAPK) signaling cascade appear to be engaged in the protective mechanism of chlorogenic acid\[[@B8]\]. Geniposidic acid, the critical active ingredient of gardenia, alleviates liver injury by enhancing the antioxidative defense system and slowing the apoptotic signaling pathways\[[@B9]\].

###### 

Mechanisms of action of compounds found in Yīn-Chén-Hāo decoction

  **Compound**                       **Pharmacological activities**                                                                                                                   **Mechanisms of action**                                                                                                                                                                                                                                                                                                                    **Ref**.
  ---------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  Chlorogenic acid                   Antibacterial, antiviral, antioxidation,                                                                                                         Reversed liver reduced GSH levels and expression of TRX, triggering GSH and TRX antioxidant systems and MAPK signaling cascade                                                                                                                                                                                                              \[8\]
  free radical scavenging,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  mutation suppression, anti-tumor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Scoparone                          Anti-inflammatory, analgesia, antioxidant, immunosuppressive, cholagogue, blood pressure, hypolipidemic, anti-asthmatic                          Inhibition of protein tyrosine kinase and release of arachidonic acid metabolites, reduced expression of tissue factor at mRNA level and thrombus generation; enhancement of prostacyclin release, protection against endothelium derived relaxing factor inactivation, and activating guanylate cyclase, relaxed bronchial smooth muscle   \[86-89\]
  Geniposide                         Anti-inflammatory, analgesia, cholagogue, laxness, soft tissue injury repair, gastric acid secretion inhibition, amylopsin secretion reduction   Enhancing antioxidative defense system and reducing apoptotic signaling pathways; regulating adipocytokine release and the expression of PPARα expression                                                                                                                                                                                   \[9,90\]
  Rhein                              Antineoplastic, anti-inflammatory, antimicrobial, immunosuppressive, diuresis and purgation, improve glycometabolic                              Inhibiting cytochrome P450 enzymes in liver microsomes                                                                                                                                                                                                                                                                                      \[91\]
  Emodin                             Antineoplastic, anti-inflammatory, antimicrobial, immunosuppressive, diuresis and purgation                                                      Inhibiting HSC activation                                                                                                                                                                                                                                                                                                                   \[92\]

GSH: Glutathione; TRX: Thioredoxin; MAPK: Mitogen-activated protein kinase; PPARα: Peroxisome proliferator activated receptor-α; HSC: Hepatic stellate cell.

One study used high-performance liquid chromatography-UV to test scoparone in rat plasma after intragastric administration of YCHD or water decoctions of capillaris, gardenia, and rhubarb separately. The study found that the scoparone level after YCHD administration was significantly higher than that of water decoctions alone. Moreover, the therapeutic effect of YCHD was found to be better than that of the herbs alone\[[@B10]\]. Another study used scoparone, geniposide, or rhein alone or in combination, and investigated their immunohistochemistry, biochemistry, metabolomics, and proteomics. The results showed that the scoparone, geniposide, and rhein combination exerts a more robust therapeutic effect than any one or two of the three individual compounds in a rat model of hepatic injury. Furthermore, scoparone, geniposide, and rhein synergistically cause intensified dynamic changes in metabolic biomarkers, regulate molecular networks through target proteins, have a synergistic effect, and activate both intrinsic and extrinsic pathways\[[@B11]\].

MECHANISMS OF YCHD EFFECTS
==========================

Liver injury repair
-------------------

The liver is a major location for the metabolism and elimination of drugs, as well as being involved in their absorption. Therefore, the liver greatly influences the pharmacokinetics of compounds. Studies demonstrate that liver injury significantly influences the pharmacokinetics of scoparone, not only *via* changes in intestinal absorption, but also *via* changes in hepatic metabolism. In one study, the absorption and distribution of scoparone was accelerated in liver-injured rats at the cost of slowed metabolism and elimination. Changes in parameters like metabolism can explain some molecular mechanisms of YCHD in the treatment of liver injury\[[@B12]\].

Research into different drug-induced liver injury forms have been conducted with YCHD. One study explored liver injury induced by α-naphthyl isothiocyanate (ANIT) and carbon tetrachloride (CCl~4~). ANIT intoxication groups were given ANIT (in corn oil at a ratio of 10:1) at a single dose of 80 mg/kg orally, while CCl~4~ intoxication groups were given CCl~4~ (in corn oil at a ratio of 1:4) at a single dose of 1 mL/kg orally. In the ANIT group, the levels of ALT, alkaline phosphatase (AKP), and TBIL were significantly higher than those in the control group. In the CCl~4~ group, the malondialdehyde content was significantly higher and superoxide dismutase and glutathione peroxidase activities were significantly lower compared with those in the control group. YCHD significantly reduced AST, ALT, and AKP levels in the ANIT group and significantly reduced AST, ALT, AKP, and malondialdehyde levels in the CCl~4~ group. In addition, YCHD was also found to increase the ratio of liver weight to body weight\[[@B13]\].

Scoparone is an important compound found in capillaris that has been shown to be hepatoprotective, effective in the treatment of liver diseases, and contribute directly to the therapeutic effect of YCHD\[[@B14]\]. The metabonomic characteristics of CCl~4~-induced hepatotoxicity and intervention with scoparone illustrate that scoparone could have hepatoprotective effects *via* multiple pathways, including primary bile acid biosynthesis and pyrimidine metabolic pathways\[[@B15]\]. The hepatoprotective effects of scoparone in rat liver injury were associated with regulated expression of six proteins that appear to be involved in antioxidation and signal transduction, energy production, immunity, metabolism, and chaperoning\[[@B16]\].

Network reconstruction techniques were used to study the treatment of alcoholic hepatitis with scoparone. The metabolites after scoparone treatment in rats with alcoholic hepatitis were observed. The results showed that scoparone could regulate dysfunctions in the citrate cycle, sphingolipid metabolism, and taurine and hypotaurine pathways\[[@B17]\]. In addition, scoparone was distributed and eliminated rapidly in rats. Tissue distribution was highest in the liver, followed by the kidney and spleen. There were lower concentrations observed in the muscle, thyroid, and adrenal gland. Scoparone was not detected in the brain, which indicates that it does not cross the blood-brain barrier after oral administration\[[@B18]\].

YCHD combined with Da-Cheng-Qi decoction can reduce Bax and caspase-3 protein expression, increase Bcl-2 protein expression, regulate the balance of Bcl-2/Bax, and treat endotoxin-induced liver cell apoptosis\[[@B19]\].

Reverse steatosis
-----------------

Recent studies have reported the efficacy of YCHD in reducing hepatic fat accumulation. Enhanced adiponectin and endothelial progenitor cells and upregulation of PPAR-γ might be responsible for the therapeutic effect of YCHD in the treatment of non-alcoholic fatty liver disease (NAFLD). In addition, the antioxidative effect of YCHD might be associated with the inhibition of hepatic-free fatty acid (FFA) concentrations and the elevation of glutathione levels in hepatic tissues. Furthermore, YCHD might promote senescence marker protein-30 metabolism, which increases resistance to hepatic oxidative stress\[[@B20]\].

In steatohepatitis experiments with rats, those treated with YCHD had lower serum ALT activity, tumor necrosis factor (TNF-α) levels, hepatic triglycerides, and FFA levels. Moreover, there was significantly less fat deposition in hepatocytes than in the steatohepatitis rats. Therefore, YCHD has good therapeutic effects on non-alcoholic steatohepatitis, can protect liver function, and can reduce fatty deposition in the liver. These effects are possibly related to reductions in FFA content and inhibition of TNF-α expression\[[@B21]\].

YCHD contains scoparone, geniposide, and rhein, with the three causing dynamic changes in metabolic biomarkers, regulating molecular networks through target proteins, having synergistic effects, and activating both intrinsic and extrinsic pathways to exert a robust therapeutic effect in a rat model of hepatic injury\[[@B11]\]. A meta-analysis was conducted on the role of YCHD in NAFLD. The results showed that YCHD can significantly regulate ALT, AST, gamma-glutamyl transpeptidase (GGT), triglycerides, total cholesterol, low-density lipoprotein cholesterol, and syndrome score. Total effective rate, syndrome effective rate, and B-type ultrasonography effective rate were significantly better in the test group than those in the control group. Therefore, YCHD has a satisfactory therapeutic effect on NAFLD\[[@B22]\].

Anti-inflammatory and anti-viral effects
----------------------------------------

Hepatitis B is a major global health problem caused by the hepatitis B virus (HBV). Many clinical studies have reported that YCHD can reduce serum transaminase activity, elevate serum albumin, reduce the ratio of albumin and globulin (A/G), improve liver function, and provide satisfactory long-term effects\[[@B23],[@B24]\]. These effects could help in the treatment of hepatitis B.

The pathogenic process of HBV is immune-mediated inflammation. Cytotoxic T lymphocytes (CTL) recognize and destroy target cells by antigen presentation, and cause target-cell apoptosis when fas ligand protein on the membrane surface unites with target-cell Fas antigen. HBV infection activates the immune system to produce and release cytokines, which promote liver inflammation and cause liver damage.

One study found that, in the treatment of chronic hepatitis B, YCHD combined with Western medicine was significantly better than Western medicine treatment alone\[[@B25]\]. In an experiment with concanavalin A-induced acute immune liver injury in mice infected with hepatitis B, YCHD was found to reduce AST, interferon-γ, and Fas gene levels, and increase the level of interleukin (IL)-4 in the liver. YCHD was also able to repair damage to liver cells, decrease the frequency of liver cell apoptosis, and reduce inflammatory response\[[@B26]\].

Drug-induced hepatitis refers to liver damage caused by drugs or their metabolites. In recent years, increased usage of new drugs and drug combinations has increased the incidence of drug-induced hepatitis. YCHD plus glycyrrhizinate or transmetil was found to be more effective than Western medicine in the treatment of drug-induced hepatitis. A control group was treated with glycyrrhizinate capsules and transmetil, while a treatment group received the same drugs plus modified YCHD. The levels of ALT, TBIL, and globulin in the treatment group were lower than those in control group after treatment (*P \<* 0.05). In addition, the level of albumin in the treatment group was higher than that in the control group\[[@B27]\].

Chronic severe hepatitis is another common type of hepatitis. The treatment of chronic severe hepatitis is difficult, and usually results in such complications as ascites, hepatic encephalopathy, gastrointestinal bleeding, and hepatorenal syndrome. Clinical research indicates that YCHD can reduce liver cell inflammation, expand intrahepatic bile capillaries, promote bile secretion, increase bile flow, improve hepatic microcirculation, reduce the absorption of intestinal toxins, and increase the excretion of bilirubin. These effects can reduce symptoms and significantly improve liver function in patients with chronic severe hepatitis\[[@B28]\]. Liver dialysis combined with YCHD is an especially effective therapeutic regimen for severe hepatitis\[[@B29]\].

Anti-fibrotic effects
---------------------

Fibrosis is a wound-healing response that engages a range of cell types and mediators to encapsulate an injury. During fibrogenesis, pathological factors including inflammation from Kupffer cells (KCs), angiogenesis, and HSC activation lead to collagen deposition\[[@B30]\]. Cirrhosis, an advanced liver disease, is characterized by fibrosis, nodule formation, and inflammation\[[@B31]\]. Despite the high incidence of hepatic fibrosis worldwide, no generally accepted antifibrogenic therapy is available. However, TCM has been widely used for treating chronic liver hepatitis and liver cirrhosis, with said treatments appearing to improve clinical symptoms, liver function, and patient quality of life\[[@B32]\].

YCHD can significantly inhibit apoptosis in liver cells, inhibit HSC activation, and inhibit KC activation, thereby protecting liver function and preventing fibrosis. In a rat model of dimethylnitrosamine (DMN)-induced liver fibrosis, YCHD significantly improved liver function, liver pathology, and reduced collagen content in liver tissue\[[@B33]\]. In addition, a DMN-induced liver fibrosis study in rats found that YCHD could decrease abnormal ALT, AST, TBIL, GGT, hydroxyproline, hyaluronic acid, laminin, collagen type IV, and amino-terminal type III procollagen peptide levels. The study also found that YCHD treatment could improve mRNA and protein levels of α-SMA (a marker of activated HSCs), restore normal albumin levels, and change amino acid metabolism. The molecular mechanism of the anti-fibrotic effects of YCHD might operate *via* suppression of HSC activation\[[@B34],[@B35]\]. In addition, the therapeutic effect of YCHD is better than that of other classic TCM formulae, such as Yīn-Chén-Si-Ni-Tang\[[@B36]\] and Gan-Lu-Xiao-Du-Dan\[[@B37]\] in the treatment of dampness-heat with liver fibrosis.

KCs are liver macrophages generally believed to be involved in liver damage *via* inflammation. There are two ways to activate KCs: the classical pathway and the alternative pathway\[[@B38],[@B39]\]. KC activation *via* the classical pathway releases inflammatory cytokines, which further activate HSCs and lead to a phenotypic transition to myofibroblasts. This transition results in excessive proliferation, as well as the synthesis and secretion of ECM components, which leads to fibrosis. The inhibition of HSC activation can reduce the biosynthesis of collagen, and therefore inhibit fibrosis.

YCHD administration attenuates liver fibrosis partially by inhibiting HSC activation, rather than promoting cell apoptosis of activated HSCs or suppressing the activation of KCs\[[@B40]\]. YCHD reduced the expression of IL-1β, CD68, Tnfrsf14, Tnfrsf9, COL1α2, MMP2, MMP23, TNF-α, and Prkcb, and increased the expression of CD14, Tf, and Igf1. These gene expression changes indicate that YCHD can inhibit liver inflammation, HSC activation, liver sinusoidal endothelial cell activation, and liver parenchymal damage *via* inhibition and regulation of the classical KC activation pathway. These effects in combination result in anti-fibrotic effects from YCHD\[[@B41]\].

YCHD can also reduce the expression of TNF, FAS, and Prkcb, and regulate the expression of CD14 genes, indicating that it can block the MAPK pathway, which inhibits hepatocyte apoptosis to prevent fibrosis\[[@B42]\].

One study found YCHD plus Huang-Qi decoction reversed liver cirrhosis in rats *via* a reduction in oxidative stress. YCHD was found to eliminate hepatic lipid peroxide formation and Huang-Qi decoction enhanced the antioxidative ability of the liver\[[@B43]\].

The pathogenesis of DMN-induced liver cirrhosis corresponds to the syndrome of interior dampness-heat with qi deficiency\[[@B44]\], and the pathogenesis of liver cirrhosis corresponds to the syndrome of interior dampness-heat\[[@B35]\].

Relief of ascites
-----------------

Cirrhosis with ascites often occurs during chronic hepatitis, with ascites often being observed in end-stage cirrhosis. The clinical manifestations of ascites are tympanites and edema. One clinical study found that YCHD combined with Jijiaolihuang bolus could clear heat and expel dampness, induce diuresis to remove edema, and reduce ascites\[[@B45]\].

Effects in other liver diseases
-------------------------------

Since YCHD can clear heat, promote diuresis, and remove jaundice, it also plays an important role in the treatment of primary liver cancer\[[@B46]\].

Liver failure is caused by extensive liver cell necrosis, which results in severely impaired liver function, while chronic liver failure results from decompensation of the liver during cirrhosis and is accompanied by a poor prognosis and high mortality rate.

HBV is the most common cause of liver failure in China. Although nucleoside analogs can inhibit viral replication in the short-term, they usually result in drug resistance in the long-term. TCM enema can solve issues such as difficulties in oral administration, effectively removing harmful bacteria in the gut, improving intestinal endotoxemia, and promoting the recovery of liver function. In patients with HBV-induced liver failure, an enema of YCHD plus colon lavage was found to result in liver function and symptom improvement, jaundice improvement, TBIL reduction, and increased prothrombin time\[[@B47]\].

One study established a rat model with hepatic failure after 70% liver resection to research the therapeutic effect of capillaris. The results showed that the herb can improve IL-6 levels, increase serum IL-6 levels, and improve survival rate in rats with liver failure after surgery\[[@B48]\].

OTHER PHARMACOLOGICAL ACTIVITIES
================================

YCHD-ameliorated alloxan (ALX) induced hyperglycemia in mice and significantly reduced fasting blood glucose (FBG) in normal mice and ALX-diabetes in mellitus model mice and rats. YCHD also improved impaired glucose tolerance in a dexamethasone-induced insulin resistance rat model and reduced 2-h post-prandial blood glucose after an oral glucose tolerance test. This suggests that YCHD has hypoglycemic effects like sulfonylurea or biguanide\[[@B49]\].

Clinical studies indicate that YCHD plus Bai-Tou-Weng decoction and hormones have a better treatment effect than Western medicine in the clinical treatment of Behçet's disease. In one study, a control group was treated with prednisone, while a treatment group was treated with the same drug plus YCHD and Bai-Tou-Weng decoction. According to the diagnostic criteria of the International Society for Behçet's Disease, the therapeutic effect in the treatment group was better than in the control group (*P \<* 0.05)\[[@B50]\].

YCHD has also been used clinically in neonatal hyperbilirubinemia\[[@B51]\], neonatal jaundice\[[@B52]\], maternal-fetal ABO blood type incompatibility\[[@B53]-[@B56]\], intrahepatic cholestasis of pregnancy\[[@B57]\], newborn pathological jaundice\[[@B58]\], and acne\[[@B59]\].

Compared with insulin and insulin analogs, combined therapy of NovoRapid and modified YCHD is an effective, safe, and economical approach to the treatment of chronic hepatitis B with diabetes\[[@B60]\].

DRUGS THAT INCLUDE THE HERBS FROM YCHD
======================================

Drugs that include the herbs found in YCHD have been on the market for many years and most have important therapeutic uses. Xiong-Dan-Yīn-Chén Oral Solution^®^ (XDYCKFY, Hei-Bao-Yao-Ye, Hei-Long-Jiang, China) is an effective and safe treatment for chronic liver diseases, and can slow down the progress of cholecystitis and cholelithiasis. Moreover, Ling-Zhi-Yīn-Chén Capsule^®^ (LZYC capsule, Zhong-Long-Yi-Yao, Hei-Long-Jiang, China) and Huang-Dan-Yīn-Chén Granule^®^ (HDYCKL, Fo-Ci-Zhi-Yao, Lan-Zhou, China) are used to improve the symptoms of idiopathic pain, abdominal distension, anorexia, malaise, fatigue, and greasy yellow tongue coating. Yīn-Chén-Tui-Huang Capsule^®^ (YCTH capsule, De Shang Yao Ye, Jilin, China) is often used in the treatment of jaundice caused by acute and chronic liver disease.

CONCLUSION
==========

This review summarized the efficacy of YCHD in liver disease from clinical trials and its mechanisms of action *in vitro* and *in vivo*. Studies indicate that YCHD can modulate various molecular pathways in liver disease. YCHD is widely used in clinical settings for the treatment of liver diseases, and could be a safe and novel therapeutic treatment for liver injury worldwide (Table [3](#T3){ref-type="table"}). Future studies on YCHD could help define its various effective constituents, molecular mechanisms, and targets that help prevent inflammation and fibrosis. Although YCHD has been used clinically for thousands of years, most studies on it are basic, and so its material basis and mechanisms remain unclear. At present, there are few multicenter, large, randomized, double-blind, controlled clinical trials on YCHD. Extensive clinical research is warranted to evaluate the safety and efficacy of YCHD alone or in combination with other drugs.

###### 

Patents containing Yīn-Chén-Hāo decoction

  **Patent**                                                                                                                                               **Patent number**
  -------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------
  YCHD preparation methods                                                                                                                                 CN101371882
  Damp-proof TCM granule and its preparation method                                                                                                        CN1781499
  Composition for improving the composition/kind of composition of crude drug powder containing rhubarb and/or its extract that can improve constipation   JP2005179316
  Medical treatment for heterotopic calcification/medicine root in TCM prescription treatment for heterotopic calcification                                JP5000961
  Kind of formula granules, including YCHD and its preparation and detection methods                                                                       CN103230453
  Method which can filtrate the material foundation of YCHD efficacy                                                                                       CN104101674

YCHD: Yīn-Chén-Hāo decoction; TCM: Traditional Chinese medicine.
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